Who is sponsoring NCT00229112?

NCT00229112 is sponsored by Merck Sharp & Dohme LLC.

What drugs are being tested in NCT00229112?

Interventions in NCT00229112: MK0826, ertapenem sodium / Duration of Treatment - 24 weeks, Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks.

What condition does NCT00229112 study?

NCT00229112 studies Foot Infections in Diabetic Patients.

Is NCT00229112 still recruiting?

NCT00229112 is currently completed. Last updated 16 February 2017.

Last reviewed 2017-02-16 · How we verify

NCT00229112

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability, of Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in Adults.

Completed Phase 3 Last updated 16 February 2017

What this trial tests

Phase 3 trial testing MK0826, ertapenem sodium / Duration of Treatment - 24 weeks in Foot Infections in Diabetic Patients in 400 participants. Completed in 1 April 2004.

Timeline

1 April 2001

Primary endpoint
1 April 2004

1 April 2004

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	400
Start date	1 April 2001
Primary completion	1 April 2004
Estimated completion	1 April 2004

Drugs / interventions tested

MK0826, ertapenem sodium / Duration of Treatment - 24 weeks — full drug profile →
Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks — full drug profile →

Conditions studied

Foot Infections in Diabetic Patients — all drugs for Foot Infections in Diabetic Patients →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

18 and older, any sex, with Foot Infections in Diabetic Patients. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Clinical Cure/Improvement at discontinuation of IV antibiotic therapy.

Sponsor's own description

This study will compare the efficacy, safety and tolerability of intravenous ertapenem versus another intravenous antibiotic in the treatment of moderate to severe diabetic foot infections.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.
Lipsky BA, Armstrong DG, Citron DM, Tice AD, et al · · 2005 · cited 161× · PMID 16291062 · DOI 10.1016/s0140-6736(05)67694-5

Verify or expand the search:

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527 · Phase 1 · not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M · Phase 3 · not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00229112 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 16 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00229112.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing